Survival outcomes of giant cell glioblastoma: Institutional experience in the management of 20 patients

摘要: Abstract Giant cell glioblastoma (GCG) is a rare subtype of (GBM) that believed to carry an improved prognosis. However, given the rarity this tumor, best management practices for GCG have yet be ascertained. Here, we present our experience in managing tumors at University California, San Francisco. Patients were retrospectively identified through chart review, and data pertaining patient demographics, treatment plans, follow-up extracted from existing medical records. Overall survival (OS) progression-free (PFS) primary secondary endpoints, respectively. In sum, 22 patients who managed or followed GCG. Most (78%) initially underwent subtotal resection as their most also received post-operative adjuvant therapy (90%), with radiation being frequently administered modality (85%). Within institutional cohort, median OS PFS 15.4 months 5.7 months, On multivariate analysis, age ( p  = 0.84), sex  = 0.05), plus temozolomide  = 0.12) not associated prolonged OS. was longer  = 0.01), receiving demonstrated 32.9 months versus 13.1 months. These findings confirm comparatively prognosis over GBM. Moreover, they suggest extent may significantly delay recurrence extend survival, combination represent optimum paradigm tumor progression.